Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 51 articles:
HTML format
Text format



Single Articles


    February 2019
  1. ARORA N, Eule C, Gupta A, Li HC, et al
    Clinicopathologic Features, Management and Outcomes of Plasmablastic Lymphoma: A Ten-Year Experience.
    Am J Hematol. 2019 Feb 7. doi: 10.1002/ajh.25432.
    PubMed     Text format    


    January 2019
  2. HONG H, Huang H, Fang X, Wang Z, et al
    A prognostic index for nasal-type early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Am J Hematol. 2019 Jan 28. doi: 10.1002/ajh.25426.
    PubMed     Text format    


  3. DE LA FUENTE MI, Alderuccio JP, Reis IM, Omuro A, et al
    Bilateral Radiation Therapy followed by Methotrexate-based Chemotherapy for Primary Vitreoretinal Lymphoma.
    Am J Hematol. 2019 Jan 21. doi: 10.1002/ajh.25414.
    PubMed     Text format     Abstract available


    December 2018
  4. CASTELLINO A, Pulido JS, Johnston PB, Ristow KM, et al
    Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
    Am J Hematol. 2018 Dec 5. doi: 10.1002/ajh.25350.
    PubMed     Text format     Abstract available


    November 2018
  5. MACKRIDES N, Chapman J, Larson MC, Ramos JC, et al
    Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma.
    Am J Hematol. 2018 Nov 25. doi: 10.1002/ajh.25357.
    PubMed     Text format    


  6. KLENER P, Salek D, Pytlik R, Mocikova H, et al
    Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.
    Am J Hematol. 2018 Nov 25. doi: 10.1002/ajh.25362.
    PubMed     Text format     Abstract available


    October 2018
  7. WONG WJ, Ruhangaza D, Manirakiza A, Omondi J, et al
    Concomitant Classic Hodgkin Lymphoma and Schistosomiasis.
    Am J Hematol. 2018 Oct 17. doi: 10.1002/ajh.25316.
    PubMed     Text format    


    September 2018
  8. POPHALI PA, Ip A, Larson MC, Rosenthal AC, et al
    The Association of Physical Activity Before and After Lymphoma Diagnosis with Survival Outcomes.
    Am J Hematol. 2018 Sep 19. doi: 10.1002/ajh.25288.
    PubMed     Text format     Abstract available


  9. TISI MC, Paolini R, Piazza F, Ravelli E, et al
    Rituximab, Bendamustine and Cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.
    Am J Hematol. 2018 Sep 5. doi: 10.1002/ajh.25278.
    PubMed     Text format    


    August 2018
  10. O'BRIEN S, Patel M, Kahl BS, Horwitz SM, et al
    Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study.
    Am J Hematol. 2018 Aug 10. doi: 10.1002/ajh.25243.
    PubMed     Text format     Abstract available


  11. BAIN BJ, Branislav C
    Monocyte adhesion with platelet satellitism and phagocytosis in Hodgkin lymphoma.
    Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25241.
    PubMed     Text format     Abstract available


    July 2018
  12. SIEGEL SE, Advani A, Seibel N, Muffly L, et al
    Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD versus pediatric-inspired regimens.
    Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25229.
    PubMed     Text format     Abstract available


  13. SIOW W, Burton K, Eagleton H, Campbell C, et al
    Transformation of follicular lymphoma.
    Am J Hematol. 2018 Jul 24. doi: 10.1002/ajh.25195.
    PubMed     Text format    


  14. HILAL T, Wang Z, Almader-Douglas D, Rosenthal A, et al
    Rituximab Maintenance Therapy for Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Am J Hematol. 2018 Jul 23. doi: 10.1002/ajh.25226.
    PubMed     Text format     Abstract available


  15. FLINN IW, Patel M, Oki Y, Horwitz S, et al
    Duvelisib, an Oral Dual PI3K-delta, gamma Inhibitor, Shows Clinical Activity in Indolent Non-Hodgkin Lymphoma in a Phase 1 Study.
    Am J Hematol. 2018 Jul 22. doi: 10.1002/ajh.25228.
    PubMed     Text format     Abstract available


  16. CASTILLO JJ, Beltran BE, Miranda RN, Young KH, et al
    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2018;93:953-962.
    PubMed     Text format     Abstract available


    June 2018
  17. BAIN BJ
    Diagnosis of follicular lymphoma from the peripheral blood.
    Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25158.
    PubMed     Text format    


  18. ROSSI C, Gilhodes J, Maerevoet M, Herbaux C, et al
    Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
    Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154.
    PubMed     Text format     Abstract available


    May 2018
  19. EKBERG S, Jerkeman M, Andersson PO, Enblad G, et al
    Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma.
    Am J Hematol. 2018 May 17. doi: 10.1002/ajh.25147.
    PubMed     Text format     Abstract available


  20. PATEL S, Li Y, Berchuck JE, Cunningham J, et al
    Did you 'miss' me? A subtle case of intravascular large B-cell lymphoma.
    Am J Hematol. 2018 May 13. doi: 10.1002/ajh.25132.
    PubMed     Text format    


  21. ANSELL SM
    Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2018;93:704-715.
    PubMed     Text format     Abstract available


    April 2018
  22. SIEGELE BJ, Nardi V
    Laboratory Testing in BCR-ABL1-like (Philadelphia-like) B-Lymphoblastic Leukemia/Lymphoma.
    Am J Hematol. 2018 Apr 26. doi: 10.1002/ajh.25126.
    PubMed     Text format     Abstract available


  23. PARDAL E, Diez Baeza E, Salas Q, Garcia T, et al
    Which very elderly diffuse large B-cell lymphoma patients can benefit from curative treatment? A multicenter, retrospective analysis by the Spanish GELTAMO group.
    Am J Hematol. 2018 Apr 15. doi: 10.1002/ajh.25107.
    PubMed     Text format     Abstract available


    February 2018
  24. CHANTEPIE SP, Garciaz S, Tchernonog E, Peyrade F, et al
    Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
    Am J Hematol. 2018 Feb 23. doi: 10.1002/ajh.25077.
    PubMed     Text format     Abstract available


  25. CARBONE A, Gloghini A
    Current and potential use of pathological targets in the treatment of Hodgkin lymphoma.
    Am J Hematol. 2018 Feb 2. doi: 10.1002/ajh.25054.
    PubMed     Text format    


  26. FREEDMAN A
    Follicular lymphoma: 2018 update on diagnosis and management.
    Am J Hematol. 2018;93:296-305.
    PubMed     Text format     Abstract available


    January 2018
  27. OLSZEWSKI AJ, Reagan JL, Castillo JJ
    Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
    Am J Hematol. 2018;93:E1-E3.
    PubMed     Text format    


    December 2017
  28. PERSKY DO, Li H, Rimsza LM, Barr PM, et al
    A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806.
    Am J Hematol. 2017 Dec 20. doi: 10.1002/ajh.25010.
    PubMed     Text format     Abstract available


  29. BOONSTRA PS, Polk A, Brown N, Hristov AC, et al
    A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
    Am J Hematol. 2017;92:1287-1294.
    PubMed     Text format     Abstract available


    November 2017
  30. RIBES D, El Hachem H, Oberic L, Vergez F, et al
    Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
    Am J Hematol. 2017 Nov 23. doi: 10.1002/ajh.24984.
    PubMed     Text format     Abstract available


  31. XAVIER AC, Epperla N, Taub JW, Costa LJ, et al
    Excess Mortality Among Ten-Year Survivors of Classical Hodgkin Lymphoma in Adolescents and Young Adults.
    Am J Hematol. 2017 Nov 8. doi: 10.1002/ajh.24964.
    PubMed     Text format     Abstract available


    October 2017
  32. ABAZA Y, Kantarjian HM, Faderl S, Jabbour E, et al
    Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma.
    Am J Hematol. 2017 Oct 19. doi: 10.1002/ajh.24947.
    PubMed     Text format     Abstract available


  33. AKHTAR S, Montoto S, Boumendil A, Finel H, et al
    High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European Society for Blood and Marrow Transplantation (EBMT)-Lymphoma Working Party.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24927.
    PubMed     Text format     Abstract available


  34. WILCOX RA
    Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2017;92:1085-1102.
    PubMed     Text format     Abstract available


  35. LOMBARDI A, Croci GA, Brazzelli V, Vecchia M, et al
    Cutaneous septic emboli from Candida glabrata in a haematological patient.
    Am J Hematol. 2017;92:1111-1112.
    PubMed     Text format    


    September 2017
  36. BELETE H, Burns LJ, Shanley R, Nayar M, et al
    Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.
    Am J Hematol. 2017;92:E529-E533.
    PubMed     Text format     Abstract available


  37. BEHRENS M, Chowdry RP, Saba S, Saba NS, et al
    A centrocyte blood count of a quarter million.
    Am J Hematol. 2017;92:972-973.
    PubMed     Text format    


    August 2017
  38. VOSE JM
    Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Am J Hematol. 2017;92:806-813.
    PubMed     Text format     Abstract available


    July 2017
  39. MALECEK MK, Petrich AM, Rozell S, Chu B, et al
    Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab.
    Am J Hematol. 2017 Jul 18. doi: 10.1002/ajh.24864.
    PubMed     Text format     Abstract available


  40. WITZIG TE, Zinzani PL, Habermann TM, Tuscano JM, et al
    Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma.
    Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24854.
    PubMed     Text format     Abstract available


  41. ARMITAGE JO
    The aggressive peripheral T-cell lymphomas: 2017.
    Am J Hematol. 2017;92:706-715.
    PubMed     Text format     Abstract available


    June 2017
  42. JAIN P, Kantarjian H, Jain N, Short NJ, et al
    Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens.
    Am J Hematol. 2017 Jun 24. doi: 10.1002/ajh.24833.
    PubMed     Text format    


  43. WITZIG TE, Johnston PB, LaPlant BR, Kurtin PJ, et al
    Long-term Follow-up of Chemoimmunotherapy with Rituximab, Oxaliplatin, Cytosine Arabinoside, Dexamethasone (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkin Lymphoma: Results of a study of the Mayo Clinic Cancer Research Consortium (MCCRC) MC0
    Am J Hematol. 2017 Jun 14. doi: 10.1002/ajh.24824.
    PubMed     Text format     Abstract available


  44. SAYGIN C, Jia X, Hill B, Dean R, et al
    Impact of Comorbidities on Outcomes of Elderly Patients with Diffuse Large B-cell Lymphoma.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24819.
    PubMed     Text format     Abstract available


  45. LANZA F, Saraceni F, Pezzi A, Martino M, et al
    A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24817.
    PubMed     Text format    


    May 2017
  46. HELBER MJ, Moore JE, Williams AM, Meacham PJ, et al
    Ibrutinib Therapy for Lymphoplasmacytic Lymphoma.
    Am J Hematol. 2017 May 24. doi: 10.1002/ajh.24795.
    PubMed     Text format    


  47. BAIR SM, Strelec L, Nagle SJ, Nasta SD, et al
    Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.
    Am J Hematol. 2017 May 16. doi: 10.1002/ajh.24792.
    PubMed     Text format     Abstract available


    April 2017
  48. BINDER M, O'Byrne MM, Maurer MJ, Ansell S, et al
    Associations between Elevated Pre-treatment Serum Cytokines and Peripheral Blood Cellular Markers of Immunosuppression in Patients with Lymphoma.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24758.
    PubMed     Text format     Abstract available


  49. HANSEN JW, Garde C, Asmar F, Tholstrup D, et al
    Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma.
    Am J Hematol. 2017 Apr 5. doi: 10.1002/ajh.24751.
    PubMed     Text format     Abstract available


    March 2017
  50. MAJOR A, Pan Z, Kamdar M
    Secondary CNS Involvement of ALK-Negative Anaplastic Large Cell Lymphoma.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24733.
    PubMed     Text format    


    January 2017
  51. RIZZO D, Viailly PJ, Mareschal S, Bohers E, et al
    Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas.
    Am J Hematol. 2017;92:68-76.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: